Phenotypes Associated with This Genotype

Genotype
MGI:5004802

• Allelic Composition: Gt(ROSA)26Sor^{tm1(gp80)Eces}/Gt(ROSA)26Sor⁺; Cd19^tm1(cre)Cgn/Cd19⁺
• Genetic Background: either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

A representative tumor in the nose of a Gt(ROSA)26Sor^{tm1(gp80)Eces}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ mouse

growth/size/body

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

mortality/aging

decreased tumor-free survival time ( J:172031 )

• mice succumb to tumors between 7 and 19 months of age

immune system

decreased B cell apoptosis ( J:172031 )

• FAS-induced

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

abnormal class switch recombination ( J:172031 )

• immunization fails to promote production of class-switched IgG1 unlike in wild-type mice

decreased B cell number ( J:172031 )

• mice exhibit fewer IgG1+ B cells compared to in wild-type mice

decreased germinal center B cell number ( J:172031 )

decreased plasma cell number ( J:172031 )

increased B cell number ( J:172031 )

• in the spleen with a slight reduction in the splenic B to T cell ratio

increased marginal zone B cell number ( J:172031 )

increased T cell number ( J:172031 )

increased macrophage cell number ( J:172031 )

absent spleen germinal center ( J:172031 )

• in non-immunized and immunized mice

decreased IgA level ( J:172031 )

• NP-stimulated

increased IgE level ( J:172031 )

• NP-stimulated

decreased IgG1 level ( J:172031 )

• resting and NP-stimulated

decreased IgG2a level ( J:172031 )

• resting and NP-stimulated

decreased IgG3 level ( J:172031 )

• resting and NP-stimulated

neoplasm

increased tumor incidence ( J:172031 )

• mice develop tumors in lymphoid tissues including nasopharynx, armpit, and inguinal region

increased sarcoma incidence ( J:172031 )

• histocytic/dendritic cell sarcoma

increased histiocytic sarcoma incidence ( J:172031 )

hematopoietic system

decreased B cell apoptosis ( J:172031 )

• FAS-induced

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

abnormal class switch recombination ( J:172031 )

• immunization fails to promote production of class-switched IgG1 unlike in wild-type mice

decreased B cell number ( J:172031 )

• mice exhibit fewer IgG1+ B cells compared to in wild-type mice

decreased germinal center B cell number ( J:172031 )

decreased plasma cell number ( J:172031 )

increased B cell number ( J:172031 )

• in the spleen with a slight reduction in the splenic B to T cell ratio

increased marginal zone B cell number ( J:172031 )

increased T cell number ( J:172031 )

increased macrophage cell number ( J:172031 )

absent spleen germinal center ( J:172031 )

• in non-immunized and immunized mice

decreased IgA level ( J:172031 )

• NP-stimulated

increased IgE level ( J:172031 )

• NP-stimulated

decreased IgG1 level ( J:172031 )

• resting and NP-stimulated

decreased IgG2a level ( J:172031 )

• resting and NP-stimulated

decreased IgG3 level ( J:172031 )

• resting and NP-stimulated

cellular

decreased B cell apoptosis ( J:172031 )

• FAS-induced